You are here

A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol

Last updated on December 1, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Kaohsiung Hsien, , Taiwan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hyperlipidemias
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult Taiwanese outpatients with type 2 diabetes mellitus and high cholesterol

- Hemoglobin A1c levels of ≤10%, LDL-C levels of ≥130 mg/dL, and serum triglyceride
levels of

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Type I diabetes mellitus

- Secondary causes of high cholesterol

- Elevated liver enzymes

NCT00645424
Pfizer
Completed
A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol
Official Title  ICMJE A Randomized, 12-Week, Open Labeled Study To Evaluate The Efficacy And Safety Of Once Daily Atorvastatin In Diabetes Mellitus Type 2 With Hyperlipidemia
Brief SummaryThe purpose of this study is to evaluate the efficacy and safety of atorvastatin for the treatment of Taiwanese patients with diabetes and high cholesterol.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hyperlipidemias
Intervention  ICMJE
  • Drug: atorvastatin
    Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
  • Drug: atorvastatin
    Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
  • Drug: atorvastatin
    Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
Study Arms  ICMJE
  • Experimental: Arm A
    Intervention: Drug: atorvastatin
  • Experimental: Arm B
    Intervention: Drug: atorvastatin
  • Experimental: Arm C
    Intervention: Drug: atorvastatin
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 24, 2008)
155
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE October 2004
Primary Completion DateNot Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult Taiwanese outpatients with type 2 diabetes mellitus and high cholesterol
  • Hemoglobin A1c levels of ?10%, LDL-C levels of ?130 mg/dL, and serum triglyceride levels of <400 mg/dL

Exclusion Criteria:

  • Type I diabetes mellitus
  • Secondary causes of high cholesterol
  • Elevated liver enzymes
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00645424
Other Study ID Numbers  ICMJE A2581123
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateApril 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now